Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Business Wire
– Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function – LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company’s board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies.“Maha joins our Board at a pivotal moment for Alto, as we continue on our path and fulfill our ambition of redefining psychiatry with our precision pipeline in areas of persistent medical need,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. “Throughout her distinguished career, Maha has been dedicate
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaBusiness Wire
- Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions [Yahoo! Finance]Yahoo! Finance
- Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderBusiness Wire
- Alto Neuroscience, Inc. (NYSE: ANRO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $32.00 price target on the stock.MarketBeat
- Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsBusiness Wire
ANRO
Sec Filings
- 4/1/24 - Form 4
- 3/29/24 - Form SC
- 3/21/24 - Form 10-K
- ANRO's page on the SEC website